ASHP therapeutic position statement on the safe use of niacin in the management of dyslipidemias

American Journal of Health-System Pharmacy

Volumn 54, Issue 24, 1997, Pages

  Britton, Mark L ^a   Bradberry, J Chris ^a   Letassy, Nancy A ^a   Mckenney, James M ^a   Sirmans, Susan M ^a  

^a NONE

Author keywords

American Society of Health System Pharmacists; Antilipemic agents; Health professions; Hyperlipidemia; Niacin; Organizations; Pharmacists; Protocols; Rationa l therapy; Toxicity

Indexed keywords

NICOTINIC ACID;

ABDOMINAL PAIN; ANOREXIA; ARTICLE; CLINICAL PHARMACY; DIARRHEA; DRUG EFFICACY; DRUG INDICATION; DRUG MONITORING; DRUG SAFETY; DYSLIPIDEMIA; GLUCOSE INTOLERANCE; HUMAN; HYPERURICEMIA; LIVER TOXICITY; NAUSEA; PHARMACIST; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; RASH; VOMITING;

EID: 33748510368     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/54.24.2815     Document Type: Article

References (20)

1. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993; 269:3015-23.
2. Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Bethesda, MD: National Heart, Lung, and Blood Institute, 1991; NIH publication no. 91-2732:70.
3. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975; 231:360-81.
4. Canner PL, Berge KG, Wenger NK et al., for the Coronary Drug Project Research Group, Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986; 8:1245-55.
5. Superko RH, Krauss RM. Coronary artery disease regression: convincing evidence for the benefit of aggressive lipoprotein management. Circulation. 1994; 90:1056-69.
6. McKenney JM, Proctor JD, Harris S et al. A comparison of the efficacy and toxic effects of sustained vs. immediate-release niacin in hypercholesterolemic patients. JAMA. 1994; 271:672-7.
7. Christensen NA, Achor RWP, Berge KG et al. Nicotinlc acid treatment of hypercholesterolemia: comparison of plain and sustained-action preparations and report of two cases of jaundice. JAMA. 1961; 177:76-80.
8. Knopp RH, Ginsberg J, Albers JJ et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism. 1985; 34:642-50.
9. Brown J, Winkelmann RK. Acanthosis nigricans: a study of 90 cases. Medicine. 1968; 47:33-51.
10. Gibbons LW, Gonzalez V, Gordon N et al. The prevalence of side effects with regular and sustained-release nicotinic acid. Am J Med. 1995; 99:378-85.
11. Parsons WB. Activation of peptic ulcer by nicotinic acid: report of five cases. JAMA. 1960; 173:92-6.
12. Gray DR, Morgan T, Chretien SD et al. Efficacy and safety of controlled-release niacin in dyslipoproteinemic veterans. Ann intern Med. 1994; 121:252-8.
13. Mullin GE, Greenson JK, Mitchell MC. Fulminant hepatic failure after ingestion of sustained-release nicotinic acid. Ann Intern Med. 1989; 111:253-5.
14. Keenan JM, Fontaine PL, Wenz JB et al. Niacin revisited: a randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia. Arch Intern Med. 1991; 151:1424-32.
15. Knopp RH, Ginsberg J, Albers JJ et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemia subjects: clues to mechanism of action of niacin. Metabolism. 1985; 34:642-50.
16. Alderman JD, Pasternak RC, Sacks FM et al. Effect of a modified, well-tolerated niacin regimen on serum total cholesterol, high density lipoprotein cholesterol and the cholesterol to high density lipoprotein ratio. Am J Cardiol. 1989; 64:725-9,
17. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Bethesda, MD: National Heart, Lung, and Blood Institute, 1993; NIH publication no. 933095:111-7.
18. Kahn SE, Beard JC, Schwartz MW et al. Increased beta-cell secretory capacity as a mechanism for islet adaptation to nicotinic acid-induced insulin resistance. Diabetes. 1989; 38:562-8.
19. Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 1988; 62:28J-34J.
20. American Heart Association Consensus Panel. Preventing heart attack and death. Circulation. 1995; 92:1-5.